This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 1999;282:625.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A new study is under way to determine if low-intensity laser treatment prevents disease progression and reduces vision loss in people who are at risk for severe age-related macular degeneration. The National Eye Institute (NEI)–sponsored effort, called the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT), will enroll a total of 1000 patients in 23 clinical centers across the country.

All participants will have one eye treated with the laser and the other eye left untreated as a control. In previous research, treatments similar to CAPT resulted in the reduction of drusen, yellow deposits that are the most common early sign of age-related macular degeneration. Throughout the trial, investigators will carefully monitor both eyes for any eye or vision problems and determine the effects of the laser treatment.

Drusen (yellow deposits), the most common early sign of age-related macular degeneration (left), may resolve after laser treatment (right). . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?